Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.48 |
| ▸ | MAP2K4 | P45985 | 6/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.47 |
| ▸ | TTK | P33981 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.44 |
| ▸ | MAPK6 | Q16659 | 4/20 | 0.44 |
| ▸ | MAPKAPK3 | Q16644 | 3/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.43 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377562 | 0.83 | NTRK1 (0.50) | MAP2K4NTRK1MAPK1MAPK6MAPKAPK3 | |
| SCHEMBL5383182 | 0.83 | MAPT (0.42) | PDE3BPDE3AP2RY12MAP2K4NTRK1 | |
| SCHEMBL8252227 | 0.80 | FAAH (0.42) | PDE3BPDE3AP2RY12MAP2K4NTRK1 | |
| SCHEMBL5386371 | 0.79 | ALOX5 (0.55) | MAP2K4TTKMAPK8KDM4EMAPT | |
| SCHEMBL5373455 | 0.77 | MAPT (0.51) | MAP2K4NTRK1TTKMAPK8MAPT | |
| SCHEMBL5374229 | 0.77 | P2RY12 (0.49) | P2RY12MAP2K4TTKMAPK8MAPT | |
| SCHEMBL5651245 | 0.77 | P2RY12 (0.49) | P2RY12MAP2K4TTKMAPK8MAPT | |
| SCHEMBL5379540 | 0.77 | MAP2K4 (0.63) | MAP2K4NTRK1MAPK1MAPK6MAPKAPK3 | |
| SCHEMBL8267795 | 0.77 | ALOX5 (0.42) | MAP2K4NTRK1TTKMAPK8KDM4E | |
| SCHEMBL5397842 | 0.77 | ALOX5 (0.42) | MAP2K4NTRK1TTKMAPK8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | PDE3B 265/4885PDE3A 272/4885P2RY12 2974/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | PDE3B 177/4885PDE3A 180/4885P2RY12 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.